Tokai Pharmaceuticals (TKAI) : The consensus on Tokai Pharmaceuticals (TKAI) based on 6 analyst recommendation on the company stock is 3.17, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst also believes that the downside risk to the stock is higher and suggests a Sell on Tokai Pharmaceuticals (TKAI).
Tokai Pharmaceuticals (TKAI) : The consensus price target for Tokai Pharmaceuticals (TKAI) is $1.68 for the short term with a standard deviation of $0.47. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $2, however, the pessimist price target for the company is $1.
Company shares have received an average consensus rating of Hold for the current week
Tokai Pharmaceuticals (NASDAQ:TKAI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.07 and $1.04 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.17. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.14, notching a gain of 5.56% for the day. The total traded volume was 996,461 . The stock had closed at $1.08 on the previous day.
Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Companys lead drug candidate galeterone is a multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. The Company is focusing its initial development of galeterone on the treatment of patients with castration resistant prostate cancer (CRPC), whose prostate tumor cells express an altered androgen receptor that is truncated. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The Company is conducting a Phase II clinical trial of galeterone, known as ARMOR2 trial, for the treatment of multiple CRPC populations.